diff --git a/pages/STOP2030___Web___Posts.md b/pages/STOP2030___Web___Posts.md
index aceca798..4e15298c 100644
--- a/pages/STOP2030___Web___Posts.md
+++ b/pages/STOP2030___Web___Posts.md
@@ -7,7 +7,7 @@
 	  
 	  The details of the REALISE study have been published in ClinicalTrials.gov and the Pan African Clinical Trial Registry. These details will soon be shared with the Institutional Review Boards (IRBs) in Ghana and Kenya, the two countries where patient recruitment and treatment administration will take place.
 	  
-	  The design of the clinical trial was lead by the teams at ISGlobal and Liconsa, with help from GHS (Ghana) and KEMRI (Kenya), as well as other members of our Consortium. 
+	  The design of the clinical trial was lead by the teams at ISGlobal and Liconsa, with support from GHS (Ghana Health Service) and KEMRI (Kenya Medical Research Institute), as well help from other members of our Consortium. 
 	  
 	  The study itself is a Cohort Event Study aimed at evaluating the safety and effectiveness of our fixed-dose coformulation (FDC) of albendazol and ivermectin within large populations, matched against the standard dose albendazole currently in use against STH. We expect to recruit around 20 thousand school-aged children between 5 and 17 years old between the two countries.